Generated by AI
Immatics N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell receptor-based immunotherapies for cancer. The company develops T-cell redirecting treatments designed to help the immune system recognize and attack solid tumors, with programs spanning adoptive cell therapies and TCR bispecifics. Its current work centers on PRAME-targeted immunotherapy, a cancer-associated target used across multiple oncology applications. Immatics N.V. operates as a research-driven oncology company with a pipeline built around precision immunotherapy platforms and collaborations that support the development of next-generation cancer treatments. Headquartered in Tübingen, Germany, the company serves the broader biopharmaceutical market through its focus on novel therapies for patients with difficult-to-treat cancers.
WebsitePaul-Ehrlich-Strasse 15-19
Tübingen, 72076
Germany
The latest articles about IMTX.
What the new PRAME data means for Immatics stock Fresh clinical results for Immatics (NasdaqCM:IMTX) are in focus after updated Phase 1b IMA402 and Phase 1 IMA203CD8 data in PRAME expressing solid tumors were shared at the 2026 ESMO meeting. The readout centers on heavily pretreated melanoma and ovarian cancer patients, where Immatics reported objective responses, disease control and durability signals, alongside what management described as manageable safety profiles for both...
Summary of Dec 5's posts. Generated by AI.
Summary of Dec 14's posts. Generated by AI.
Summary of Jun 20's posts. Generated by AI.
Investors talking about IMTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.